| Bioactivity | DS28120313 (compound 32) is an orally hepcidin production inhibitor with an IC50 of 0.093 μM[1]. | ||||||||||||
| Target | IC50: 0.093 μM (hepcidin production) | ||||||||||||
| In Vivo | DS28120313 (deliver orally; 30 mg/kg; 30 min before IL-6 administration) inhibits hepcidin production and reduces the blood hepcidin level in IL-6 induced acute inflammatory C57BL/6 mouse model[1]. | ||||||||||||
| Name | DS28120313 | ||||||||||||
| CAS | 2146177-09-3 | ||||||||||||
| Formula | C16H17N5O2 | ||||||||||||
| Molar Mass | 311.34 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Fukuda T, et al. Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives. Bioorg Med Chem Lett. 2017 Dec 1;27(23):5252-5257. |